282 related articles for article (PubMed ID: 18046666)
1. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
Maione A; Nicolucci A; Craig JC; Tognoni G; Moschetta A; Palasciano G; Pugliese G; Procaccini DA; Gesualdo L; Pellegrini F; Strippoli GF;
J Nephrol; 2007; 20(6):646-55. PubMed ID: 18046666
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
3. [Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO).].
Maione A; Nicolucci A; Craig JC; Tognoni G; Moschetta A; Palasciano G; Pugliese G; Procaccini DA; Gesualdo L; Pellegrini F; Strippoli GF
G Ital Nefrol; 2007; 24(5):446-56. PubMed ID: 17886213
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
6. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
Kalaitzidis R; Bakris G
Postgrad Med; 2009 Mar; 121(2):77-88. PubMed ID: 19332965
[TBL] [Abstract][Full Text] [Related]
7. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
8. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
9. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
11. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
Bommer WJ
Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
[TBL] [Abstract][Full Text] [Related]
12. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
13. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
Cotter J; Oliveira P; Cunha P; Polónia J
Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
[TBL] [Abstract][Full Text] [Related]
14. Have angiotensin receptor blockers lived up to expectations?
Fitchett D
Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354
[TBL] [Abstract][Full Text] [Related]
15. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
Saglimbene V; Palmer SC; Ruospo M; Natale P; Maione A; Nicolucci A; Vecchio M; Tognoni G; Craig JC; Pellegrini F; Lucisano G; Hegbrant J; Ariano R; Lamacchia O; Sasso A; Morano S; Filardi T; De Cosmo S; Pugliese G; Procaccini DA; Gesualdo L; Palasciano G; Johnson DW; Tonelli M; Strippoli GFM;
J Am Soc Nephrol; 2018 Dec; 29(12):2890-2899. PubMed ID: 30420421
[TBL] [Abstract][Full Text] [Related]
16. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
Böhm M
Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the renin-angiotensin system: why and in which patients.
Berra K; Miller NH
J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
[TBL] [Abstract][Full Text] [Related]
20. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]